查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1548166

全球血友病治療市場研究報告 - 2024 年至 2032 年產業分析、規模、佔有率、成長、趨勢與預測

Global Hemophilia Treatment Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032
出版日期: | 出版商: Value Market Research | 英文 378 Pages | 商品交期: 最快1-2個工作天內

價格

全球血友病治療市場需求預計將從 2023 年的 173.2 億美元達到近 298.2 億美元的市場規模，2024-2032 年研究期間複合年成長率為 6.22%。

血友病是一種罕見的遺傳性疾病，其特徵是血液無法正常凝固，導致受傷或手術後長時間出血。血友病治療涉及旨在替代或增強血液中缺乏的凝血因子的療法。這些治療方法包括濃縮凝血因子，它可以從血漿中提取或透過重組 DNA 技術生產。此外，基因療法有望透過糾正潛在的遺傳缺陷來提供長期解決方案。血友病的有效管理對於預防和控制出血事件至關重要，從而提高患者的生活品質。

市場動態

血友病患病率不斷上升，全球約有萬分之一的人受到影響，推動了對有效血友病治療方案的需求。重組因子療法的進步和新型基因療法的開發為改善患者治療結果和提供治癒方法提供了重要機會。例如，基因療法的最新創新在臨床試驗中顯示出有希望的結果，為長期解決方案提供了潛力。此外，提高意識和更好的診斷能力有助於早期發現和治療，進一步推動血友病治療市場的成長。政府的支持性措施和研究資助也為先進療法的持續開發和可近性提供了機會。然而，創新療法的高成本和發展中地區的獲取機會有限可能會限制血友病治療市場的成長。

研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具也對全球血友病治療市場的各個細分市場進行了包容性評估。血友病治療產業的成長和趨勢為本研究提供了整體方法。

市場區隔

血友病治療市場報告的這一部分提供了國家和區域層面細分市場的詳細資料，從而幫助策略師確定相應產品或服務的目標人群以及即將到來的機會。

依疾病類型

  • A 型血友病（重度、中度、輕度）
  • 血友病 B（重度、中度、輕度）
  • 其他疾病類型

按產品分類

  • 重組凝血因子濃縮物（因子 Vill、因子 IX）
  • 血漿衍生凝血因子濃縮物（因子 Vill、因子 IX）
  • 延長半衰期產品（Factor Vill、Factor IX）
  • 去氨加壓素
  • 抗纖維蛋白溶解劑
  • 基因治療產品

按患者

  • 兒科（0 至 4、5 至 13、14 至 l8）
  • 成人（19 至 44、45 歲以上）

按治療

  • 預防
  • 一經請求

透過治療

  • 因子替代療法
  • 非因子替代療法

按藥物類別

  • 加壓素
  • 凝血因子

依給藥途徑

  • 可注射
  • 鼻噴劑
  • 口服

按最終用途

  • 醫院
  • 診所
  • 血友病治療中心
  • 其他最終用戶

區域分析

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲血友病治療市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。血友病治療市場的主要參與者包括拜耳公司、百健公司、Biotest AG（Grifols，SA）、BioMarin Pharmaceutical Inc、CSL Behring LLC、Ferring BV.、基因泰克公司（羅氏控股公司）、Kedrion SPA、諾和諾德A/S、Octapharma AG、輝瑞公司、賽諾菲 SA、瑞典 Orphan Biovitrum AB、武田製藥有限公司。本節包含競爭格局的整體視圖，包括各種策略發展，例如關鍵併購、未來產能、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

目錄

第1章：前言

  • 報告說明
    • 客觀的
    • 目標受眾
    • 獨特的銷售主張 (USP) 和產品
  • 研究範圍
  • 研究方法
    • 市場研究過程
    • 市場研究方法論

第 2 章：執行摘要

  • 市場亮點
  • 全球市場概況

第 3 章：血友病治療 - 產業分析

  • 簡介 - 市場動態
  • 市場促進因素
  • 市場限制
  • 機會
  • 產業動態
  • 波特五力分析
  • 市場吸引力分析
    • 按疾病類型分類的市場吸引力分析
    • 按產品分類的市場吸引力分析
    • 患者市場吸引力分析
    • 按處理方式進行的市場吸引力分析
    • 按治療方法進行的市場吸引力分析
    • 按藥品類別分類的市場吸引力分析
    • 按給藥途徑進行的市場吸引力分析
    • 按最終用途分類的市場吸引力分析
    • 市場吸引力分析：按地區

第 4 章：價值鏈分析

  • 價值鏈分析
  • 原料分析
    • 原料清單
    • 原料廠商清單
    • 主要原物料價格走勢
  • 潛在買家名單
  • 行銷管道
    • 直效行銷
    • 間接行銷
    • 行銷通路發展趨勢

第 5 章：全球血友病治療市場分析：依疾病類型

  • 依疾病類型概述
  • 按疾病類型進行歷史和預測資料分析
  • A 型血友病（重度、中度、輕度）
  • 血友病 B（重度、中度、輕度）
  • 其他疾病類型

第 6 章：全球血友病治療市場分析：依產品

  • 概述（按產品）
  • 按產品分類的歷史和預測資料分析
  • 重組凝血因子濃縮物（因子 Vill、因子 IX）
  • 血漿衍生凝血因子濃縮物（因子 Vill、因子 IX）
  • 延長半衰期產品（Factor Vill、Factor IX）
  • 去氨加壓素
  • 抗纖維蛋白溶解劑
  • 基因治療產品

第 7 章：全球血友病治療市場分析：依患者分類

  • 患者概述
  • 患者的歷史和預測數據分析
  • 兒科（0 至 4、5 至 13、14 至 l8）
  • 成人（19 至 44、45 歲以上）

第 8 章：全球血友病治療市場分析：依治療分類

  • 按治療概述
  • 依處理方式進行歷史與預測資料分析
  • 預防
  • 一經請求

第 9 章：全球血友病治療市場分析：依治療方法

  • 治療概述
  • 按治療進行歷史和預測數據分析
  • 因子替代療法
  • 非因子替代療法

第 10 章：全球血友病治療市場分析：依藥物類別

  • 按藥物類別概述
  • 按藥物類別進行歷史和預測數據分析
  • 加壓素
  • 凝血因子

第 11 章：全球血友病治療市場分析：依給藥途徑

  • 依給藥途徑概述
  • 按給藥途徑進行歷史和預測資料分析
  • 可注射
  • 鼻噴劑
  • 口服

第 12 章：全球血友病治療市場分析：依最終用途分類

  • 按最終用途分類的概述
  • 按最終用途分類的歷史和預測資料分析
  • 醫院
  • 診所
  • 血友病治療中心
  • 其他最終用戶

第 13 章：全球血友病治療市場分析：依地理位置

  • 區域展望
  • 介紹
  • 北美銷售分析
    • 概覽、歷史與預測資料銷售分析
    • 北美按細分市場銷售分析
    • 北美按國家銷售分析
    • 美國銷售分析
    • 加拿大銷售分析
    • 墨西哥銷售分析
  • 歐洲銷售分析
    • 概覽、歷史與預測資料銷售分析
    • 歐洲按細分市場銷售分析
    • 歐洲按國家銷售分析
    • 英國銷售分析
    • 法國銷售分析
    • 德國銷售分析
    • 義大利銷售分析
    • 俄羅斯銷售分析
    • 歐洲其他地區銷售分析
  • 亞太地區銷售分析
    • 概覽、歷史與預測資料銷售分析
    • 亞太地區按細分市場銷售分析
    • 亞太地區按國家銷售分析
    • 中國銷售分析
    • 印度銷售分析
    • 日本銷售分析
    • 韓國銷售分析
    • 澳洲銷售分析
    • 東南亞銷售分析
    • 亞太地區其他地區銷售分析
  • 拉丁美洲銷售分析
    • 概覽、歷史與預測資料銷售分析
    • 拉丁美洲按細分市場銷售分析
    • 拉丁美洲按國家銷售分析
    • 巴西銷售分析
    • 阿根廷銷售分析
    • 秘魯銷售分析
    • 智利銷售分析
    • 拉丁美洲其他地區銷售分析
  • 中東和非洲銷售分析
    • 概覽、歷史與預測資料銷售分析
    • 中東和非洲按細分市場銷售分析
    • 中東和非洲按國家銷售分析
    • 沙烏地阿拉伯銷售分析
    • 阿拉伯聯合大公國銷售分析
    • 以色列銷售分析
    • 南非銷售分析
    • 中東其他地區和非洲銷售分析

第 14 章：血友病治療公司的競爭格局

  • 血友病治療市場競爭
  • 夥伴關係/協作/協議
  • 併購
  • 新產品發布
  • 其他發展

第 15 章：公司簡介

  • 頂級公司市佔率分析
  • 市場集中度
  • Bayer AG
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Biogen Inc.
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Biotest AG (Grifols SA)
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Takeda Pharmaceutical Company Limited
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • BioMarin Pharmaceutical Inc
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • CSL Behring LLC
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Ferring BV.
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Genentech Inc. (Roche Holding AG)
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Kedrion SPA
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Novo Nordisk A/S
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Octapharma AG
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Pfizer Inc.
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Sanofi SA
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Swedish Orphan Biovitrum AB
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態

註 - 在公司概況中，財務詳細資訊和最新發展視情況而定，或對私人公司而言可能不包括在內

Product Code: VMR112115486

The global demand for Hemophilia Treatment Market is presumed to reach the market size of nearly USD 29.82 Billion by 2032 from USD 17.32 Billion in 2023 with a CAGR of 6.22% under the study period 2024-2032.

Hemophilia is a rare genetic disorder that features the inability of blood to clot properly, leading to prolonged bleeding after injuries or surgeries. Hemophilia treatment involves therapies designed to replace or enhance deficient clotting factors in the blood. These treatments include clotting factor concentrates, which can be derived from blood plasma or produced through recombinant DNA technology. Additionally, gene therapy is promising in providing a long-term solution by correcting the underlying genetic defect. Effective management of hemophilia is crucial for preventing and controlling bleeding episodes, thereby improving patients' quality of life.

MARKET DYNAMICS

The increasing prevalence of hemophilia, with approximately 1 in 10,000 individuals affected globally, drives the demand for effective hemophilia treatment options. Advances in recombinant factor therapies and the development of novel gene therapies offer significant opportunities to improve patient outcomes and provide a cure. For instance, recent innovations in gene therapy have demonstrated promising results in clinical trials, offering the potential for long-term solutions. Additionally, increasing awareness and better diagnostic capabilities contribute to early detection and treatment, further driving hemophilia treatment market growth. Supportive government initiatives and funding for research also provide opportunities for the continued development and accessibility of advanced therapies. However, the high cost of innovative therapies and limited access in developing regions may restrain hemophilia treatment market growth.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Hemophilia Treatment. The growth and trends of Hemophilia Treatment industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Hemophilia Treatment market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Disease Type

  • Hemophilia A (Severe, Moderate, Mild)
  • Hemophilia B (Severe, Moderate, Mild)
  • Other Disease Types

By Product

  • Recombinant Coagulation Factor Concentrates (Factor Vill, Factor IX)
  • Plasma-Derived Coagulation Factor Concentrates (Factor Vill, Factor IX)
  • Extended Half-Life Products (Factor Vill, Factor IX)
  • Desmopressin
  • Antifibrinolytic Agents
  • Gene Therapy Products

By Patient

  • Pediatric (0 To 4, 5 To 13, 14 to l8)
  • Adult (19 To 44, 45+)

By Treatment

  • Prophylaxis
  • On Demand

By Therapy

  • Factor Replacement Therapy
  • Non-Factor Replacement Therapy

By Drug Class

  • Vasopressin
  • Coagulation Factors

By Route of Administration

  • Injectable
  • Nasal Spray
  • Oral

By End-use

  • Hospitals
  • Clinics
  • Hemophilia Treatment Centers
  • Other End-User

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Hemophilia Treatment market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Hemophilia Treatment market include Bayer AG, Biogen Inc., Biotest AG (Grifols, S.A.), BioMarin Pharmaceutical Inc, CSL Behring LLC, Ferring BV., Genentech Inc. (Roche Holding AG), Kedrion S.P.A, Novo Nordisk A/S, Octapharma AG, Pfizer Inc., Sanofi SA, Swedish Orphan Biovitrum AB, Takeda Pharmaceutical Company Limited. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Report Description
    • 1.1.1 Objective
    • 1.1.2 Target Audience
    • 1.1.3 Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1 Market Research Process
    • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3. HEMOPHILIA TREATMENT - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Disease Type
    • 3.7.2 Market Attractiveness Analysis By Product
    • 3.7.3 Market Attractiveness Analysis By Patient
    • 3.7.4 Market Attractiveness Analysis By Treatment
    • 3.7.5 Market Attractiveness Analysis By Therapy
    • 3.7.6 Market Attractiveness Analysis By Drug Class
    • 3.7.7 Market Attractiveness Analysis By Route of Administration
    • 3.7.8 Market Attractiveness Analysis By End-use
    • 3.7.9 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1 List of Raw Materials
    • 4.2.2 Raw Material Manufactures List
    • 4.2.3 Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1 Direct Marketing
    • 4.4.2 Indirect Marketing
    • 4.4.3 Marketing Channel Development Trend

5. GLOBAL HEMOPHILIA TREATMENT MARKET ANALYSIS BY DISEASE TYPE

  • 5.1. Overview By Disease Type
  • 5.2. Historical and Forecast Data Analysis By Disease Type
  • 5.3. Hemophilia A (Severe, Moderate, Mild) Historic and Forecast Sales By Regions
  • 5.4. Hemophilia B (Severe, Moderate, Mild) Historic and Forecast Sales By Regions
  • 5.5. Other Disease Types Historic and Forecast Sales By Regions

6. GLOBAL HEMOPHILIA TREATMENT MARKET ANALYSIS BY PRODUCT

  • 6.1. Overview By Product
  • 6.2. Historical and Forecast Data Analysis By Product
  • 6.3. Recombinant Coagulation Factor Concentrates (Factor Vill, Factor IX) Historic and Forecast Sales By Regions
  • 6.4. Plasma-Derived Coagulation Factor Concentrates (Factor Vill, Factor IX) Historic and Forecast Sales By Regions
  • 6.5. Extended Half-Life Products (Factor Vill, Factor IX) Historic and Forecast Sales By Regions
  • 6.6. Desmopressin Historic and Forecast Sales By Regions
  • 6.7. Antifibrinolytic Agents Historic and Forecast Sales By Regions
  • 6.8. Gene Therapy Products Historic and Forecast Sales By Regions

7. GLOBAL HEMOPHILIA TREATMENT MARKET ANALYSIS BY PATIENT

  • 7.1. Overview By Patient
  • 7.2. Historical and Forecast Data Analysis By Patient
  • 7.3. Pediatric (0 To 4, 5 To 13, 14 to l8) Historic and Forecast Sales By Regions
  • 7.4. Adult (19 To 44, 45+) Historic and Forecast Sales By Regions

8. GLOBAL HEMOPHILIA TREATMENT MARKET ANALYSIS BY TREATMENT

  • 8.1. Overview By Treatment
  • 8.2. Historical and Forecast Data Analysis By Treatment
  • 8.3. Prophylaxis Historic and Forecast Sales By Regions
  • 8.4. On Demand Historic and Forecast Sales By Regions

9. GLOBAL HEMOPHILIA TREATMENT MARKET ANALYSIS BY THERAPY

  • 9.1. Overview By Therapy
  • 9.2. Historical and Forecast Data Analysis By Therapy
  • 9.3. Factor Replacement Therapy Historic and Forecast Sales By Regions
  • 9.4. Non-Factor Replacement Therapy Historic and Forecast Sales By Regions

10. GLOBAL HEMOPHILIA TREATMENT MARKET ANALYSIS BY DRUG CLASS

  • 10.1. Overview By Drug Class
  • 10.2. Historical and Forecast Data Analysis By Drug Class
  • 10.3. Vasopressin Historic and Forecast Sales By Regions
  • 10.4. Coagulation Factors Historic and Forecast Sales By Regions

11. GLOBAL HEMOPHILIA TREATMENT MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

  • 11.1. Overview By Route of Administration
  • 11.2. Historical and Forecast Data Analysis By Route of Administration
  • 11.3. Injectable Historic and Forecast Sales By Regions
  • 11.4. Nasal Spray Historic and Forecast Sales By Regions
  • 11.5. Oral Historic and Forecast Sales By Regions

12. GLOBAL HEMOPHILIA TREATMENT MARKET ANALYSIS BY END-USE

  • 12.1. Overview By End-use
  • 12.2. Historical and Forecast Data Analysis By End-use
  • 12.3. Hospitals Historic and Forecast Sales By Regions
  • 12.4. Clinics Historic and Forecast Sales By Regions
  • 12.5. Hemophilia Treatment Centers Historic and Forecast Sales By Regions
  • 12.6. Other End-User Historic and Forecast Sales By Regions

13. GLOBAL HEMOPHILIA TREATMENT MARKET ANALYSIS BY GEOGRAPHY

  • 13.1. Regional Outlook
  • 13.2. Introduction
  • 13.3. North America Sales Analysis
    • 13.3.1 Overview, Historic and Forecast Data Sales Analysis
    • 13.3.2 North America By Segment Sales Analysis
    • 13.3.3 North America By Country Sales Analysis
    • 13.3.4 United States Sales Analysis
    • 13.3.5 Canada Sales Analysis
    • 13.3.6 Mexico Sales Analysis
  • 13.4. Europe Sales Analysis
    • 13.4.1 Overview, Historic and Forecast Data Sales Analysis
    • 13.4.2 Europe By Segment Sales Analysis
    • 13.4.3 Europe By Country Sales Analysis
    • 13.4.4 United Kingdom Sales Analysis
    • 13.4.5 France Sales Analysis
    • 13.4.6 Germany Sales Analysis
    • 13.4.7 Italy Sales Analysis
    • 13.4.8 Russia Sales Analysis
    • 13.4.9 Rest Of Europe Sales Analysis
  • 13.5. Asia Pacific Sales Analysis
    • 13.5.1 Overview, Historic and Forecast Data Sales Analysis
    • 13.5.2 Asia Pacific By Segment Sales Analysis
    • 13.5.3 Asia Pacific By Country Sales Analysis
    • 13.5.4 China Sales Analysis
    • 13.5.5 India Sales Analysis
    • 13.5.6 Japan Sales Analysis
    • 13.5.7 South Korea Sales Analysis
    • 13.5.8 Australia Sales Analysis
    • 13.5.9 South East Asia Sales Analysis
    • 13.5.10 Rest Of Asia Pacific Sales Analysis
  • 13.6. Latin America Sales Analysis
    • 13.6.1 Overview, Historic and Forecast Data Sales Analysis
    • 13.6.2 Latin America By Segment Sales Analysis
    • 13.6.3 Latin America By Country Sales Analysis
    • 13.6.4 Brazil Sales Analysis
    • 13.6.5 Argentina Sales Analysis
    • 13.6.6 Peru Sales Analysis
    • 13.6.7 Chile Sales Analysis
    • 13.6.8 Rest of Latin America Sales Analysis
  • 13.7. Middle East & Africa Sales Analysis
    • 13.7.1 Overview, Historic and Forecast Data Sales Analysis
    • 13.7.2 Middle East & Africa By Segment Sales Analysis
    • 13.7.3 Middle East & Africa By Country Sales Analysis
    • 13.7.4 Saudi Arabia Sales Analysis
    • 13.7.5 UAE Sales Analysis
    • 13.7.6 Israel Sales Analysis
    • 13.7.7 South Africa Sales Analysis
    • 13.7.8 Rest Of Middle East And Africa Sales Analysis

14. COMPETITIVE LANDSCAPE OF THE HEMOPHILIA TREATMENT COMPANIES

  • 14.1. Hemophilia Treatment Market Competition
  • 14.2. Partnership/Collaboration/Agreement
  • 14.3. Merger And Acquisitions
  • 14.4. New Product Launch
  • 14.5. Other Developments

15. COMPANY PROFILES OF HEMOPHILIA TREATMENT INDUSTRY

  • 15.1. Top Companies Market Share Analysis
  • 15.2. Market Concentration Rate
  • 15.3. Bayer AG
    • 15.3.1 Company Overview
    • 15.3.2 Company Revenue
    • 15.3.3 Products
    • 15.3.4 Recent Developments
  • 15.4. Biogen Inc.
    • 15.4.1 Company Overview
    • 15.4.2 Company Revenue
    • 15.4.3 Products
    • 15.4.4 Recent Developments
  • 15.5. Biotest AG (Grifols S.A.)
    • 15.5.1 Company Overview
    • 15.5.2 Company Revenue
    • 15.5.3 Products
    • 15.5.4 Recent Developments
  • 15.6. Takeda Pharmaceutical Company Limited
    • 15.6.1 Company Overview
    • 15.6.2 Company Revenue
    • 15.6.3 Products
    • 15.6.4 Recent Developments
  • 15.7. BioMarin Pharmaceutical Inc
    • 15.7.1 Company Overview
    • 15.7.2 Company Revenue
    • 15.7.3 Products
    • 15.7.4 Recent Developments
  • 15.8. CSL Behring LLC
    • 15.8.1 Company Overview
    • 15.8.2 Company Revenue
    • 15.8.3 Products
    • 15.8.4 Recent Developments
  • 15.9. Ferring BV.
    • 15.9.1 Company Overview
    • 15.9.2 Company Revenue
    • 15.9.3 Products
    • 15.9.4 Recent Developments
  • 15.10. Genentech Inc. (Roche Holding AG)
    • 15.10.1 Company Overview
    • 15.10.2 Company Revenue
    • 15.10.3 Products
    • 15.10.4 Recent Developments
  • 15.11. Kedrion S.P.A
    • 15.11.1 Company Overview
    • 15.11.2 Company Revenue
    • 15.11.3 Products
    • 15.11.4 Recent Developments
  • 15.12. Novo Nordisk A/S
    • 15.12.1 Company Overview
    • 15.12.2 Company Revenue
    • 15.12.3 Products
    • 15.12.4 Recent Developments
  • 15.13. Octapharma AG
    • 15.13.1 Company Overview
    • 15.13.2 Company Revenue
    • 15.13.3 Products
    • 15.13.4 Recent Developments
  • 15.14. Pfizer Inc.
    • 15.14.1 Company Overview
    • 15.14.2 Company Revenue
    • 15.14.3 Products
    • 15.14.4 Recent Developments
  • 15.15. Sanofi SA
    • 15.15.1 Company Overview
    • 15.15.2 Company Revenue
    • 15.15.3 Products
    • 15.15.4 Recent Developments
  • 15.16. Swedish Orphan Biovitrum AB
    • 15.16.1 Company Overview
    • 15.16.2 Company Revenue
    • 15.16.3 Products
    • 15.16.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies

LIST OF TABLES

  • Market Snapshot
  • Drivers: Impact Analysis
  • Restraints: Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • Analysis By Disease Type (USD MN)
  • Hemophilia A (Severe, Moderate, Mild) Market Sales By Geography (USD MN)
  • Hemophilia B (Severe, Moderate, Mild) Market Sales By Geography (USD MN)
  • Other Disease Types Market Sales By Geography (USD MN)
  • Analysis By Product (USD MN)
  • Recombinant Coagulation Factor Concentrates (Factor Vill, Factor IX) Market Sales By Geography (USD MN)
  • Plasma-Derived Coagulation Factor Concentrates (Factor Vill, Factor IX) Market Sales By Geography (USD MN)
  • Extended Half-Life Products (Factor Vill, Factor IX) Market Sales By Geography (USD MN)
  • Desmopressin Market Sales By Geography (USD MN)
  • Antifibrinolytic Agents Market Sales By Geography (USD MN)
  • Gene Therapy Products Market Sales By Geography (USD MN)
  • Analysis By Patient (USD MN)
  • Pediatric (0 To 4, 5 To 13, 14 to l8) Market Sales By Geography (USD MN)
  • Adult (19 To 44, 45+) Market Sales By Geography (USD MN)
  • Analysis By Treatment (USD MN)
  • Prophylaxis Market Sales By Geography (USD MN)
  • On Demand Market Sales By Geography (USD MN)
  • Analysis By Therapy (USD MN)
  • Factor Replacement Therapy Market Sales By Geography (USD MN)
  • Non-Factor Replacement Therapy Market Sales By Geography (USD MN)
  • Analysis By Drug Class (USD MN)
  • Vasopressin Market Sales By Geography (USD MN)
  • Coagulation Factors Market Sales By Geography (USD MN)
  • Analysis By Route of Administration (USD MN)
  • Injectable Market Sales By Geography (USD MN)
  • Nasal Spray Market Sales By Geography (USD MN)
  • Oral Market Sales By Geography (USD MN)
  • Analysis By End-use (USD MN)
  • Hospitals Market Sales By Geography (USD MN)
  • Clinics Market Sales By Geography (USD MN)
  • Hemophilia Treatment Centers Market Sales By Geography (USD MN)
  • Other End-User Market Sales By Geography (USD MN)
  • Global Hemophilia Treatment Market Sales By Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United States Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate By Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • South East Asia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Hemophilia Treatment Report
  • Market Research Process
  • Market Research Methodology
  • Global Hemophilia Treatment Market Size, By Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis By Disease Type
  • Market Attractiveness Analysis By Product
  • Market Attractiveness Analysis By Patient
  • Market Attractiveness Analysis By Treatment
  • Market Attractiveness Analysis By Therapy
  • Market Attractiveness Analysis By Drug Class
  • Market Attractiveness Analysis By Route of Administration
  • Market Attractiveness Analysis By End-use
  • Market Attractiveness Analysis By Region
  • Value Chain Analysis
  • Global Market Analysis By Disease Type (USD MN)
  • Hemophilia A (Severe, Moderate, Mild) Market Sales By Geography (USD MN)
  • Hemophilia B (Severe, Moderate, Mild) Market Sales By Geography (USD MN)
  • Other Disease Types Market Sales By Geography (USD MN)
  • Global Market Analysis By Product (USD MN)
  • Recombinant Coagulation Factor Concentrates (Factor Vill, Factor IX) Market Sales By Geography (USD MN)
  • Plasma-Derived Coagulation Factor Concentrates (Factor Vill, Factor IX) Market Sales By Geography (USD MN)
  • Extended Half-Life Products (Factor Vill, Factor IX) Market Sales By Geography (USD MN)
  • Desmopressin Market Sales By Geography (USD MN)
  • Antifibrinolytic Agents Market Sales By Geography (USD MN)
  • Gene Therapy Products Market Sales By Geography (USD MN)
  • Global Market Analysis By Patient (USD MN)
  • Pediatric (0 To 4, 5 To 13, 14 to l8) Market Sales By Geography (USD MN)
  • Adult (19 To 44, 45+) Market Sales By Geography (USD MN)
  • Global Market Analysis By Treatment (USD MN)
  • Prophylaxis Market Sales By Geography (USD MN)
  • On Demand Market Sales By Geography (USD MN)
  • Global Market Analysis By Therapy (USD MN)
  • Factor Replacement Therapy Market Sales By Geography (USD MN)
  • Non-Factor Replacement Therapy Market Sales By Geography (USD MN)
  • Global Market Analysis By Drug Class (USD MN)
  • Vasopressin Market Sales By Geography (USD MN)
  • Coagulation Factors Market Sales By Geography (USD MN)
  • Global Market Analysis By Route of Administration (USD MN)
  • Injectable Market Sales By Geography (USD MN)
  • Nasal Spray Market Sales By Geography (USD MN)
  • Oral Market Sales By Geography (USD MN)
  • Global Market Analysis By End-use (USD MN)
  • Hospitals Market Sales By Geography (USD MN)
  • Clinics Market Sales By Geography (USD MN)
  • Hemophilia Treatment Centers Market Sales By Geography (USD MN)
  • Other End-User Market Sales By Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.